Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy.
- Gastl M Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- Gruner C Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- Labucay K Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- Gotschy A Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- Von Spiczak J Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland.
- Polacin M Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland.
- Boenner F Department of Cardiology, Pneumology and Angiology, Heinrich Heine University, Dusseldorf, Germany.
- Kelm M Department of Cardiology, Pneumology and Angiology, Heinrich Heine University, Dusseldorf, Germany.
- Ruschitzka F Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- Alkadhi H Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland.
- Kozerke S Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland.
- Manka R Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
- 2020-03-24
Published in:
- Open heart. - 2020
MRI
arrhythmias
myocardial fibrosis
myocardial ischaemia and infarction (IHD)
ventricular hypertrophy
Adult
Aged
Arrhythmias, Cardiac
Biomarkers
Cardiomyopathy, Hypertrophic
Disease Progression
Female
Fibrosis
Heart Failure
Humans
Magnetic Resonance Imaging, Cine
Male
Middle Aged
Myocardium
Predictive Value of Tests
Prognosis
Retrospective Studies
Risk Factors
Troponin T
English
Background
Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate the association of T2* values or fibrosis with cardiovascular events in HCM.
Methods
The relationship between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was added to the model. Patients were subdivided into groups according to T2* value quartiles.
Results
47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of heart failure. T2*≤28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2* of non-obstructive HCM showed a significant association with ventricular events in univariate analysis, but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure.
Conclusions
Decreased T2* values by CMR only provide a small association with arrhythmic events in HCM, especially in non-obstructive HCM. No information is added for heart failure.
Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate the association of T2* values or fibrosis with cardiovascular events in HCM.
Methods
The relationship between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was added to the model. Patients were subdivided into groups according to T2* value quartiles.
Results
47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of heart failure. T2*≤28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2* of non-obstructive HCM showed a significant association with ventricular events in univariate analysis, but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure.
Conclusions
Decreased T2* values by CMR only provide a small association with arrhythmic events in HCM, especially in non-obstructive HCM. No information is added for heart failure.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1136/openhrt-2019-001152
- PMID 32201584
- Persistent URL
- https://sonar.ch/global/documents/158455
Statistics
Document views: 22
File downloads:
- fulltext.pdf: 0